Skip to main content
Top
Published in: BMC Psychiatry 1/2017

Open Access 01-12-2017 | Research article

Antipsychotic prescribing for vulnerable populations: a clinical audit at an acute Australian mental health unit at two-time points

Authors: Sara S McMillan, Sara Jacobs, Louise Wilson, Theo Theodoros, Gail Robinson, Claire Anderson, Gabor Mihala, Amanda J Wheeler

Published in: BMC Psychiatry | Issue 1/2017

Login to get access

Abstract

Background

Antipsychotics are recognised as a critical intervention for schizophrenia and bipolar disorder. Guidelines globally endorse the routine practice of antipsychotic monotherapy, at the minimum effective dose. Even in treatment-resistant schizophrenia, clozapine use is endorsed before combining antipsychotics.
This aim of this study was to review antipsychotic polytherapy alone, high-dose therapy alone, polytherapy and high-dose prescribing patterns in adults discharged from an inpatient mental health unit at two time-points, and the alignment of this prescribing with clinical guideline recommendations. Additionally, associations with polytherapy and high-dose antipsychotic prescribing, including patient and clinical characteristics, were explored.

Methods

A retrospective clinical audit of 400 adults (200 patients at two different time-points) discharged with at least one antipsychotic. Preliminary findings and education sessions were provided to physicians between Cohorts. Outcomes (polytherapy alone, high-dose therapy alone, polytherapy and high-dose therapy) were compared between study Cohorts using chi-squared and rank-sum tests. Associations between outcomes and covariates were assessed using multivariable logistic regression.

Results

Most patients (62.5%) were discharged on a single antipsychotic within the recommended dose range. There was a clear preference for prescribing second generation antipsychotics, and in this respect, prescribing is aligned with current evidence-based guidelines. However, sub-optimal prescribing practices were identified for both Cohorts in relation to polytherapy and high-dose antipsychotic rates. Involuntary treatment, frequent hospitalisations and previous clozapine use significantly increased the risk of all three prescribing outcomes at discharge.

Conclusions

In a significant minority, antipsychotic prescribing did not align with clinical guidelines despite increased training, indicating that the education program alone was ineffective at positively influencing antipsychotic prescribing practices. Further consideration should be given when prescribing antipsychotics for involuntary patients, people with frequent hospitalisations, and those who have previously trialled clozapine.
Literature
1.
go back to reference National Institute for Health and Care Excellence: Psychosis and schizophrenia in adults: prevention and management. In: NICE guidelines [CG178]. vol. 2016; 2014. National Institute for Health and Care Excellence: Psychosis and schizophrenia in adults: prevention and management. In: NICE guidelines [CG178]. vol. 2016; 2014.
2.
go back to reference Galletly C, Castle D, Dark F, Humberstone V, Jablensky A, Killackey E, Kulkarni J, McGorry P, Nielssen O, Tran N. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders. Aust N Z J Psychiatry. 2016;50:410–72.CrossRefPubMed Galletly C, Castle D, Dark F, Humberstone V, Jablensky A, Killackey E, Kulkarni J, McGorry P, Nielssen O, Tran N. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders. Aust N Z J Psychiatry. 2016;50:410–72.CrossRefPubMed
3.
go back to reference McIntyre R, Katzman M. The role of atypical antipsychotics in bipolar depression and anxiety disorders. Bipolar Disord. 2003;5(Suppl 2):20–35.CrossRefPubMed McIntyre R, Katzman M. The role of atypical antipsychotics in bipolar depression and anxiety disorders. Bipolar Disord. 2003;5(Suppl 2):20–35.CrossRefPubMed
4.
go back to reference National Institute for Health and Care Excellence: Bipolar disorder: assessment and management. In: NICE guidelines [CG185]. vol. 2016; 2014. National Institute for Health and Care Excellence: Bipolar disorder: assessment and management. In: NICE guidelines [CG185]. vol. 2016; 2014.
5.
go back to reference Barnes TR. Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2011;25:567–620.CrossRefPubMed Barnes TR. Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2011;25:567–620.CrossRefPubMed
6.
go back to reference Barnes TRE, Paton C. Antipsychotic Polypharmacy in Schizophrenia: Benefits and Risks. CNS Drugs. 2011;25:383–99.CrossRefPubMed Barnes TRE, Paton C. Antipsychotic Polypharmacy in Schizophrenia: Benefits and Risks. CNS Drugs. 2011;25:383–99.CrossRefPubMed
7.
go back to reference Lochmann van Bennekom MW, Gijsman HJ, Zitman FG. Antipsychotic polypharmacy in psychotic disorders: a critical review of neurobiology, efficacy, tolerability and cost effectiveness. J Psychopharmacol. 2013;27:327–36.CrossRefPubMed Lochmann van Bennekom MW, Gijsman HJ, Zitman FG. Antipsychotic polypharmacy in psychotic disorders: a critical review of neurobiology, efficacy, tolerability and cost effectiveness. J Psychopharmacol. 2013;27:327–36.CrossRefPubMed
8.
go back to reference Mortimer AM, Singh P, Shepherd CJ, Puthiryackal J. Clozapine for treatment-resistant schizophrenia: National Institute of Clinical Excellence (NICE) guidance in the real world. Clin Schizophr Relat Psychoses. 2010;4:49–55.CrossRefPubMed Mortimer AM, Singh P, Shepherd CJ, Puthiryackal J. Clozapine for treatment-resistant schizophrenia: National Institute of Clinical Excellence (NICE) guidance in the real world. Clin Schizophr Relat Psychoses. 2010;4:49–55.CrossRefPubMed
9.
go back to reference Dold M, Leucht S. Pharmacotherapy of treatment-resistant schizophrenia: a clinical perspective. Evid Based Ment Health. 2014;17:33–7.CrossRefPubMed Dold M, Leucht S. Pharmacotherapy of treatment-resistant schizophrenia: a clinical perspective. Evid Based Ment Health. 2014;17:33–7.CrossRefPubMed
10.
go back to reference Dey S, Menkes DB, Obertova Z, Chaudhuri S, Mellsop G. Antipsychotic prescribing and its correlates in New Zealand. Australas Psychiatry. 2016;24:360–4.CrossRefPubMed Dey S, Menkes DB, Obertova Z, Chaudhuri S, Mellsop G. Antipsychotic prescribing and its correlates in New Zealand. Australas Psychiatry. 2016;24:360–4.CrossRefPubMed
11.
go back to reference Mojtabai R, Olfson M. National trends in psychotropic medication polypharmacy in office-based psychiatry. Arch Gen Psychiatry. 2010;67:26–36.CrossRefPubMed Mojtabai R, Olfson M. National trends in psychotropic medication polypharmacy in office-based psychiatry. Arch Gen Psychiatry. 2010;67:26–36.CrossRefPubMed
12.
go back to reference Patel MX, Bishara D, Jayakumar S, Zalewska K, Shiers D, Crawford MJ, Cooper SJ. Quality of prescribing for schizophrenia: Evidence from a national audit in England and Wales. Eur Neuropsychopharmacol. 2014;24:499–509.CrossRefPubMed Patel MX, Bishara D, Jayakumar S, Zalewska K, Shiers D, Crawford MJ, Cooper SJ. Quality of prescribing for schizophrenia: Evidence from a national audit in England and Wales. Eur Neuropsychopharmacol. 2014;24:499–509.CrossRefPubMed
13.
go back to reference Gallego JA, Bonetti J, Zhang J, Kane JM, Correll CU. Prevalence and correlates of antipsychotic polypharmacy: A systematic review and meta-regression of global and regional trends from the 1970s to 2009. Schizophr Res. 2012;138:18–28.CrossRefPubMedPubMedCentral Gallego JA, Bonetti J, Zhang J, Kane JM, Correll CU. Prevalence and correlates of antipsychotic polypharmacy: A systematic review and meta-regression of global and regional trends from the 1970s to 2009. Schizophr Res. 2012;138:18–28.CrossRefPubMedPubMedCentral
14.
go back to reference Waterreus A, Morgan VA, Castle D, Galletly C, Jablensky A, Di Prinzio P, Shah S. Medication for psychosis--consumption and consequences: the second Australian national survey of psychosis. Aust N Z J Psychiatry. 2012;46:762–73.CrossRefPubMed Waterreus A, Morgan VA, Castle D, Galletly C, Jablensky A, Di Prinzio P, Shah S. Medication for psychosis--consumption and consequences: the second Australian national survey of psychosis. Aust N Z J Psychiatry. 2012;46:762–73.CrossRefPubMed
15.
go back to reference Davis JM, Chen N. Dose response and dose equivalence of antipsychotics. J Clin Psychopharmacol. 2004;24:192–208.CrossRefPubMed Davis JM, Chen N. Dose response and dose equivalence of antipsychotics. J Clin Psychopharmacol. 2004;24:192–208.CrossRefPubMed
16.
go back to reference Fleischhacker WW, Uchida H. Critical review of antipsychotic polypharmacy in the treatment of schizophrenia. Int J Neuropsychopharmacol. 2014;17:1083–93.CrossRefPubMed Fleischhacker WW, Uchida H. Critical review of antipsychotic polypharmacy in the treatment of schizophrenia. Int J Neuropsychopharmacol. 2014;17:1083–93.CrossRefPubMed
18.
go back to reference Lelliott P, Paton C, Harrington M, Konsolaki M, Sensky T, Okocha C. The influence of patient variables on polypharmacy and combined high dose of antipsychotic drugs prescribed for in-patients. Psychol Bull. 2002;26:411–4.CrossRef Lelliott P, Paton C, Harrington M, Konsolaki M, Sensky T, Okocha C. The influence of patient variables on polypharmacy and combined high dose of antipsychotic drugs prescribed for in-patients. Psychol Bull. 2002;26:411–4.CrossRef
19.
go back to reference Correll CU, Shaikh L, Gallego JA, Nachbar J, Olshanskiy V, Kishimoto T, Kane JM. Antipsychotic polypharmacy: a survey study of prescriber attitudes, knowledge and behavior. Schizophr Res. 2011;131:58–62.CrossRefPubMedPubMedCentral Correll CU, Shaikh L, Gallego JA, Nachbar J, Olshanskiy V, Kishimoto T, Kane JM. Antipsychotic polypharmacy: a survey study of prescriber attitudes, knowledge and behavior. Schizophr Res. 2011;131:58–62.CrossRefPubMedPubMedCentral
20.
go back to reference Sun F, Stock EM, Copeland LA, Zeber JE, Ahmedani BK, Morissette SB. Polypharmacy with antipsychotic drugs in patients with schizophrenia: trends in multiple health care systems. Am J Health Syst Pharm. 2014;71:728–38.CrossRefPubMedPubMedCentral Sun F, Stock EM, Copeland LA, Zeber JE, Ahmedani BK, Morissette SB. Polypharmacy with antipsychotic drugs in patients with schizophrenia: trends in multiple health care systems. Am J Health Syst Pharm. 2014;71:728–38.CrossRefPubMedPubMedCentral
22.
go back to reference John AP, Gee T, Alexander S, Ramankutty P, Dragovic M. Prevalence and nature of antipsychotic polypharmacy among inpatients with schizophrenia spectrum disorders at an Australian mental health service. Australas Psychiatry. 2014;22:546–50.CrossRefPubMed John AP, Gee T, Alexander S, Ramankutty P, Dragovic M. Prevalence and nature of antipsychotic polypharmacy among inpatients with schizophrenia spectrum disorders at an Australian mental health service. Australas Psychiatry. 2014;22:546–50.CrossRefPubMed
23.
go back to reference Sim K, Su A, Fujii S, Yang SY, Chong MY, Ungvari GS, Si T, Chung EK, Tsang HY, Chan YH, et al. Antipsychotic polypharmacy in patients with schizophrenia: a multicentre comparative study in East Asia. Br J Clin Pharmacol. 2004;58:178–83.CrossRefPubMedPubMedCentral Sim K, Su A, Fujii S, Yang SY, Chong MY, Ungvari GS, Si T, Chung EK, Tsang HY, Chan YH, et al. Antipsychotic polypharmacy in patients with schizophrenia: a multicentre comparative study in East Asia. Br J Clin Pharmacol. 2004;58:178–83.CrossRefPubMedPubMedCentral
24.
go back to reference Paton C, Barnes TRE, Cavanagh M-R, Taylor D, Lelliott P. High-dose and combination antipsychotic prescribing in acute adult wards in the UK: the challenges posed by p.r.n. prescribing. Br J Psychiatry. 2008;192:435–9.CrossRefPubMed Paton C, Barnes TRE, Cavanagh M-R, Taylor D, Lelliott P. High-dose and combination antipsychotic prescribing in acute adult wards in the UK: the challenges posed by p.r.n. prescribing. Br J Psychiatry. 2008;192:435–9.CrossRefPubMed
25.
go back to reference Roh D, Chang J-G, Kim C-H, Cho H-S, An SK, Jung Y-C. Antipsychotic polypharmacy and high-dose prescription in schizophrenia: a 5-year comparison. Aust N Z J Psychiatry. 2014;48:52–60.CrossRefPubMed Roh D, Chang J-G, Kim C-H, Cho H-S, An SK, Jung Y-C. Antipsychotic polypharmacy and high-dose prescription in schizophrenia: a 5-year comparison. Aust N Z J Psychiatry. 2014;48:52–60.CrossRefPubMed
26.
go back to reference Gisev N, Bell JS, Chen TF. Factors associated with antipsychotic polypharmacy and high-dose antipsychotics among individuals receiving compulsory treatment in the community. J Clin Psychopharmacol. 2014;34:307–12.CrossRefPubMed Gisev N, Bell JS, Chen TF. Factors associated with antipsychotic polypharmacy and high-dose antipsychotics among individuals receiving compulsory treatment in the community. J Clin Psychopharmacol. 2014;34:307–12.CrossRefPubMed
27.
go back to reference dosReis S, Zito JM, Buchanan RW, Lehman AF. Antipsychotic dosing and concurrent psychotropic treatments for Medicaid-insured individuals with schizophrenia. Schizophr Bull. 2002;28:607–17.CrossRefPubMed dosReis S, Zito JM, Buchanan RW, Lehman AF. Antipsychotic dosing and concurrent psychotropic treatments for Medicaid-insured individuals with schizophrenia. Schizophr Bull. 2002;28:607–17.CrossRefPubMed
28.
go back to reference Wheeler AJ. Treatment Pathway and Patterns of Clozapine Prescribing for Schizophrenia in New Zealand. Ann Pharmacother. 2008;42:852–60.CrossRefPubMed Wheeler AJ. Treatment Pathway and Patterns of Clozapine Prescribing for Schizophrenia in New Zealand. Ann Pharmacother. 2008;42:852–60.CrossRefPubMed
29.
go back to reference Arnold LM, Strakowski SM, Schwiers ML, Amicone J, Fleck DE, Corey KB, Farrow JE. Sex, ethnicity, and antipsychotic medication use in patients with psychosis. Schizophr Res. 2004;66:169–75.CrossRefPubMed Arnold LM, Strakowski SM, Schwiers ML, Amicone J, Fleck DE, Corey KB, Farrow JE. Sex, ethnicity, and antipsychotic medication use in patients with psychosis. Schizophr Res. 2004;66:169–75.CrossRefPubMed
30.
go back to reference Connolly A, Taylor D, Sparshatt A, Cornelius V. Antipsychotic prescribing in Black and White hospitalised patients. J Psychopharmacol. 2011;25:704–9.CrossRefPubMed Connolly A, Taylor D, Sparshatt A, Cornelius V. Antipsychotic prescribing in Black and White hospitalised patients. J Psychopharmacol. 2011;25:704–9.CrossRefPubMed
31.
go back to reference Wheeler A, Humberstone V, Robinson E. Ethnic comparisons of antipsychotic use in schizophrenia. Aust N Z J Psychiatry. 2008;42:863–73.CrossRefPubMed Wheeler A, Humberstone V, Robinson E. Ethnic comparisons of antipsychotic use in schizophrenia. Aust N Z J Psychiatry. 2008;42:863–73.CrossRefPubMed
32.
go back to reference Wheeler A, Humberstone V, Robinson E, Sheridan J, Joyce P. Impact of audit and feedback on antipsychotic prescribing in schizophrenia. J Eval Clin Pract. 2009;15:441–50.CrossRefPubMed Wheeler A, Humberstone V, Robinson E, Sheridan J, Joyce P. Impact of audit and feedback on antipsychotic prescribing in schizophrenia. J Eval Clin Pract. 2009;15:441–50.CrossRefPubMed
33.
go back to reference Ministry of Health. Toward clinical excellence: an introduction to clinical audit, peer review and other clinical practice pmprovements. Wellington: Ministry of Health; 2002. Ministry of Health. Toward clinical excellence: an introduction to clinical audit, peer review and other clinical practice pmprovements. Wellington: Ministry of Health; 2002.
34.
go back to reference National Institute for Clinical Excellence. Principles for Best Practice in Clinical Audit. Oxon: Radcliffe Medical Press Ltd; 2002. National Institute for Clinical Excellence. Principles for Best Practice in Clinical Audit. Oxon: Radcliffe Medical Press Ltd; 2002.
35.
go back to reference Queensland Government: Mental Health Act 2000. Queensland; 2000. Queensland Government: Mental Health Act 2000. Queensland; 2000.
37.
go back to reference Taylor D, Paton C, Kapur S. The Maudsley Prescribing Guidelines in Psychiatry, 11 edn: UK: Wiley-Blackwell; 2012. Taylor D, Paton C, Kapur S. The Maudsley Prescribing Guidelines in Psychiatry, 11 edn: UK: Wiley-Blackwell; 2012.
38.
go back to reference Joint Formulary Committee. British National Formulary (BNF) 69. London: BMJ Publishing Group Ltd, Royal Pharmaceutical Society; 2015. Joint Formulary Committee. British National Formulary (BNF) 69. London: BMJ Publishing Group Ltd, Royal Pharmaceutical Society; 2015.
39.
go back to reference Campos Mendes J, Azeredo-Lopes S, Cardoso G. Patterns of antipsychotics' prescription in Portuguese acute psychiatric wards: A cross-sectional study. Psychiatry research. 2016;246:142–8.CrossRefPubMed Campos Mendes J, Azeredo-Lopes S, Cardoso G. Patterns of antipsychotics' prescription in Portuguese acute psychiatric wards: A cross-sectional study. Psychiatry research. 2016;246:142–8.CrossRefPubMed
40.
go back to reference Malhi G, Adams D, Bernardi E, Miller M, Mulder R, Walter G, Smith B. Time to 'get real': preliminary insights into the long-term management of schizophrenia. Australas Psychiatry. 2010;18:115–9.CrossRefPubMed Malhi G, Adams D, Bernardi E, Miller M, Mulder R, Walter G, Smith B. Time to 'get real': preliminary insights into the long-term management of schizophrenia. Australas Psychiatry. 2010;18:115–9.CrossRefPubMed
41.
go back to reference Forrester T, Siskind D, Winckel K, Wheeler A, Hollingworth S. Increasing Clozapine Dispensing Trends in Queensland, Australia 2004-2013. Pharmacopsychiatry. 2015;48:164–9.CrossRefPubMed Forrester T, Siskind D, Winckel K, Wheeler A, Hollingworth S. Increasing Clozapine Dispensing Trends in Queensland, Australia 2004-2013. Pharmacopsychiatry. 2015;48:164–9.CrossRefPubMed
43.
go back to reference Nielsen J, Dahm M, Lublin H, Taylor D. Psychiatrists’ attitude towards and knowledge of clozapine treatment. J Psychopharmacol. 2010;24:965–71.CrossRefPubMed Nielsen J, Dahm M, Lublin H, Taylor D. Psychiatrists’ attitude towards and knowledge of clozapine treatment. J Psychopharmacol. 2010;24:965–71.CrossRefPubMed
44.
go back to reference Wheeler AJ, Feetam CL, Harrison J. Pathway to clozapine use: a comparison between a patient cohort from New Zealand and a cohort from the United Kingdom. Clin Drug Investig. 2014;34:203–11.CrossRefPubMed Wheeler AJ, Feetam CL, Harrison J. Pathway to clozapine use: a comparison between a patient cohort from New Zealand and a cohort from the United Kingdom. Clin Drug Investig. 2014;34:203–11.CrossRefPubMed
45.
go back to reference Mace S, Taylor D. Reducing the rates of prescribing high-dose antipsychotics and polypharmacy on psychiatric inpatient and intensive care units: results of a 6-year quality improvement programme. Ther Adv Psychopharmacol. 2015;5:4–12.CrossRefPubMedPubMedCentral Mace S, Taylor D. Reducing the rates of prescribing high-dose antipsychotics and polypharmacy on psychiatric inpatient and intensive care units: results of a 6-year quality improvement programme. Ther Adv Psychopharmacol. 2015;5:4–12.CrossRefPubMedPubMedCentral
46.
go back to reference Santone G, Bellantuono C, Rucci P, Picardi A, Preti A, de Girolamo G. Patient characteristics and process factors associated with antipsychotic polypharmacy in a nationwide sample of psychiatric inpatients in Italy. Pharmacoepidemiol Drug Saf. 2011;20:441–9.CrossRefPubMed Santone G, Bellantuono C, Rucci P, Picardi A, Preti A, de Girolamo G. Patient characteristics and process factors associated with antipsychotic polypharmacy in a nationwide sample of psychiatric inpatients in Italy. Pharmacoepidemiol Drug Saf. 2011;20:441–9.CrossRefPubMed
47.
go back to reference Hung GB, Cheung HK. Predictors of high-dose antipsychotic prescription in psychiatric patients in Hong Kong. Hong Kong Med J. 2008;14:35–9.PubMed Hung GB, Cheung HK. Predictors of high-dose antipsychotic prescription in psychiatric patients in Hong Kong. Hong Kong Med J. 2008;14:35–9.PubMed
48.
go back to reference Gisev N, Bell JS, Chen TF. A retrospective study of psychotropic drug use among individuals with mental illness issued a community treatment order. Int J Clin Pract. 2014;68:236–44.CrossRefPubMed Gisev N, Bell JS, Chen TF. A retrospective study of psychotropic drug use among individuals with mental illness issued a community treatment order. Int J Clin Pract. 2014;68:236–44.CrossRefPubMed
49.
go back to reference Younas M, Bradley E, Holmes N, Sud D, Maidment ID. Mental health pharmacists views on shared decision-making for antipsychotics in serious mental illness. Int J Clin Pharm. 2016;38:1191–9.CrossRefPubMedPubMedCentral Younas M, Bradley E, Holmes N, Sud D, Maidment ID. Mental health pharmacists views on shared decision-making for antipsychotics in serious mental illness. Int J Clin Pharm. 2016;38:1191–9.CrossRefPubMedPubMedCentral
50.
go back to reference Tungaraza TE, Zahid U, Venkataramaiah B. Polypharmacy and high-dose antipsychotics at the time of discharge from acute psychiatric wards. BJ Psych Bulletin. 2011;35:288–92. Tungaraza TE, Zahid U, Venkataramaiah B. Polypharmacy and high-dose antipsychotics at the time of discharge from acute psychiatric wards. BJ Psych Bulletin. 2011;35:288–92.
51.
go back to reference Wheeler A. Explicit versus implicit review to explore combination antipsychotic prescribing. J Eval Clin Pract. 2009;15:685–91.CrossRefPubMed Wheeler A. Explicit versus implicit review to explore combination antipsychotic prescribing. J Eval Clin Pract. 2009;15:685–91.CrossRefPubMed
52.
go back to reference Wheeler A, Vanderpyl J, Carswell C, Stojkovic M, Robinson E. Explicit review of risperidone long-acting injection prescribing practice. J Clin Pharm Ther. 2011;36:651–63.CrossRefPubMed Wheeler A, Vanderpyl J, Carswell C, Stojkovic M, Robinson E. Explicit review of risperidone long-acting injection prescribing practice. J Clin Pharm Ther. 2011;36:651–63.CrossRefPubMed
53.
go back to reference Kadra G, Stewart R, Shetty H, Jackson RG, Greenwood MA, Roberts A, Chang C-K, MacCabe JH, Hayes RD. Extracting antipsychotic polypharmacy data from electronic health records: developing and evaluating a novel process. BMC Psychiatry. 2015;15:166.CrossRefPubMedPubMedCentral Kadra G, Stewart R, Shetty H, Jackson RG, Greenwood MA, Roberts A, Chang C-K, MacCabe JH, Hayes RD. Extracting antipsychotic polypharmacy data from electronic health records: developing and evaluating a novel process. BMC Psychiatry. 2015;15:166.CrossRefPubMedPubMedCentral
Metadata
Title
Antipsychotic prescribing for vulnerable populations: a clinical audit at an acute Australian mental health unit at two-time points
Authors
Sara S McMillan
Sara Jacobs
Louise Wilson
Theo Theodoros
Gail Robinson
Claire Anderson
Gabor Mihala
Amanda J Wheeler
Publication date
01-12-2017
Publisher
BioMed Central
Published in
BMC Psychiatry / Issue 1/2017
Electronic ISSN: 1471-244X
DOI
https://doi.org/10.1186/s12888-017-1295-1

Other articles of this Issue 1/2017

BMC Psychiatry 1/2017 Go to the issue